Scientists get first look at T cell responses in Ebola virus survivors
23 July 2018
A study of the immune response in Ebola survivors suggests that a vaccine targeting not only the glycoprotein but Ebola's nucleoprotein would likely be more effective than the current vaccines that only express the glycoprotein.
Going forward, the researchers plan to study samples from people who may have been infected with Ebola virus but never presented with symptoms, such as the family members of victims of the epidemic. They also hope to uncover why some people survived Ebola virus infection, only to experience reactivation of the virus months or years later.